IOVA
Iovance Biotherapeutics, Inc. Common Stock
Nasdaq · usd
Iovance Biotherapeutics, Inc. Common Stock (IOVA) trades at $7.76 (+1.70%) as of 7:58:27 PM EST on Nov 13, 2026, -47.28% over the past month. Market cap is $3.59B, with 4.2 days to cover in short interest.
Stock performance
How Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock has performed from one day to one year, with its 52-week range.
- 1D
- +1.70%
- 1W
- -3.48%
- 1M
- -47.28%
- YTD
- +184.25%
- 1Y
- +220.66%
- 52-wk range
- $2.08 – $15.37
Key statistics
Today's trading snapshot for IOVA: day range, open, previous close, volume and market cap.
- Day range
- $7.46 – $7.83
- Open
- $7.80
- Prev close
- $7.63
- Volume
- 11.68M
- Market cap
- $3.59B
- Shares out
- 462.66M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Iovance Biotherapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 9.47
- P/B
- 4.42
- P/FCF
- —
- ROE
- -27.1%
- ROA
- -22.3%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Iovance Biotherapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 5, 2026
On November 5, 2026, Iovance Biotherapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026, and an update on recent developments.
- Investor presentationNov 5, 2026
On November 5, 2026, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.
- Clinical trial resultsOct 29, 2026
On October 29, 2026, Iovance Biotherapeutics, Inc. (the "Company") issued a press release announcing updated results from Cohorts 1 and 2 of the Company's Phase 2 IOV-LUN-202 trial and a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer.
- Investor presentationOct 5, 2026
On October 5, 2026, Iovance Biotherapeutics, Inc. updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.1.
- Guidance issuance or updateSep 29, 2026
On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance.
IOVA short interest
How heavily IOVA is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.2
- Short interest
- 65.19M
- Avg volume
- 15.64M
As of · reported to FINRA twice monthly.
IOVA news
The latest news and headlines about Iovance Biotherapeutics, Inc. Common Stock (IOVA).
- IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline ProgresspositiveZacks Investment Research· Nov 6, 2026
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedpositiveZacks Investment Research· Nov 4, 2026
- Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?positiveZacks Investment Research· Nov 3, 2026
- Iovance Gears Up to Report Q3 Earnings: Here's What to ExpectpositiveZacks Investment Research· Nov 2, 2026
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthpositiveZacks Investment Research· Oct 30, 2026
Frequently asked questions
What is the Iovance Biotherapeutics, Inc. Common Stock (IOVA) stock price today?
Iovance Biotherapeutics, Inc. Common Stock (IOVA) is trading at $7.76 (+1.70% on the day) as of 7:58:27 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Iovance Biotherapeutics, Inc. Common Stock?
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient.
What is the short interest in IOVA?
As of Oct 30, 2026, IOVA has 65.19M shares short and 4.2 days to cover.
What exchange is IOVA listed on?
Iovance Biotherapeutics, Inc. Common Stock (IOVA) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of IOVA with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a IOVA analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.